Seattle, WA RevealDx announced today that Dr. Lauren Nicola has joined the company as their CMO. Chris Wood, CEO of RevealDx, said, “We are thrilled to have such an accomplished clinical and business leader on our team. The appointment of Dr. Nicola as our CMO also reaffirms our belief that medical imaging AI should be … RevealDx announces appointment of Lauren Nicola M.D. as Chief Medical Officer
News
Strategic partner Volpara Health to distribute RevealAI-Lung™ in Australia and New Zealand Wellington, NZ, 21 September 2022: RevealDx and Volpara Health (ASX: VHT) today announced that RevealAI-Lung™, an AI-powered software application that helps accelerate lung cancer diagnosis and reduce unnecessary procedures, has received Therapeutic Goods Administration (TGA) clearance from the Australian Government Department of Health. … RevealDx’s precision medicine software for lung nodule risk analysis receives regulatory clearance in Australia and New Zealand
The shortcomings of the area under the receiver operating characteristic curve (ROC AUC) have been well understood for years. When used to assess Medical Imaging AI, it’s primary weakness is the lack of focus on clinical impact. Why then, have Medical Imaging AI companies have been slow to move beyond AUC? In this new article, our … New Post by our CEO: When Assessing Medical Imaging AI Performance, ROC AUC is Not Enough
“The Takeaway: These results suggest that a CADx lung nodule solution like RevealAI-Lung could significantly improve lung nodule severity assessments. Considering the clinical importance of early and accurate diagnosis of high-risk nodules and the many negatives associated with improper diagnosis of low-risk nodules (costs, efficiency, procedures, patient burden), that could be a big deal.” Click … Imaging Wire Reports: CADx’s Lung Nodule Impact
RevealDx appoints contextflow as its exclusive distributor in the European Union and selected territories. The companies also announce trial installation discounts for select customers. Seattle, WA – August 3, 2022 – Chest specialists RevealDx and contextflow announced today an agreement for exclusive distribution of RevealDx’ products in the EU and other selected territories. The companies … RevealDx and contextflow team up to improve lung cancer screening in the EU via enhanced nodule characterization